Delivery Order SPE2DB24D3014-SPE2DB25FKUMB
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Trintellix 10 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $1,309.08. The award, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-set-aside competitive award to the prime contractor. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,673.88 to AmerisourceBergen Drug Corp for the supply of Trintellix 20 mg tablets (30-count units) on August 19, 2025, with completion targeted for August 20, 2025. This competitively awarded, non-set-aside contract reflects a firm fixed-price delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a total value of $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Trintellix 5 mg tablets (30-count) with a contract ceiling value of $4,978.44. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,183.42 to AmerisourceBergen Drug Corp for Trintellix 5 mg tablets (30-count packages) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,427.12 for 30 tablets of Trintellix 20 mg on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Trintellix is a psychiatric medication used to treat major depressive disorder, reflecting the breadth...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Trintellix 20 mg tablets in a quantity of 30 units. This firm fixed-price delivery order, valued at $2,747.66, represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The contract was completed on August 8, 2025, with performance fulfilled at the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $1,621.39 to AmerisourceBergen Drug Corp for 30 tablets of Trintellix 5 mg, a pharmaceutical product used in the treatment of major depressive disorder. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 12, 2025. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,575.48, is for the supply of Trintellix 5 mg tablets and does not have a set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a...
- This is a $4,039.61 delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 30-count tablets of the medication Trintellix 10 mg. The award was made on September 13, 2021, with a completion date of September 14, 2021. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and AmerisourceBergen...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,208.34 for 30 tablets of Trintellix 20 mg, a prescription antidepressant used to treat major depressive disorder. This firm fixed price delivery order, awarded on August 11, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The award involved no set-aside...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUMBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,392.88 to AmerisourceBergen Drug Corp for the supply of Trintellix 10 mg tablets (30-count units) on August 27, 2025, with completion scheduled for August 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework. The pharmaceutical will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally, including support to the Defense Health Agency and U.S. Coast Guard. The arrangement reflects DLA's strategy of engaging major pharmaceutical distributors through flexible contract mechanisms to ensure consistent availability of both brand-name and generic medications across multiple therapeutic domains for federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 8/27/25 |